scholarly journals MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

2021 ◽  
Author(s):  
Qi Hao ◽  
Xinyue Liu ◽  
Yongping Zhang ◽  
Dongmei Zhang ◽  
Boran Li ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
Poor Outcomes ◽  
Relapsed Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation

2009 ◽  
Vol 84 (3) ◽  
pp. 188-190 ◽  
Author(s):  
Benjamin Gesundheit ◽  
Michael Y. Shapira ◽  
Igor B. Resnick ◽  
Avraham Amar ◽  
Don Kristt ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
Relapsed Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Analysis of Clinical Features and Prognosis in Patients with Refractory/Relapsed Acute Myeloid Leukemia- Results from Our Center

2020 ◽  
pp. 1-6
Author(s):  
Bao-An Chen ◽  
Xiaoyu Li ◽  
Fei Wang ◽  
Yixin Zhou ◽  
Bao-An Chen
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Clinical Features ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem ◽  
Relapsed Acute Myeloid Leukemia ◽  
Acute Myeloid

Objective: To analyse the clinical features and survival of patients with refractory/relapsed acute myeloid leukemia (AML) in our center, thus, to find out whether there is a trend of improvement in the survival of these patients in the past years and to search for prognostic factors which are associated with patients’ survival. Method: A total of 45 patients with refractory/relapsed AML were retrospectively reviewed. Clinical data, including gender, age, FAB classification of AML, performance status (PS), cytogenetic and molecular abnormities, complete remission (CR) duration, choices of treatment (whether to undergo hematopoietic stem cell transplantation) before and after relapse. The Kaplan-Meier method and the Log-rank test were conducted to determine the influence of those above factors on the patients’ survival. Results: The mean survival time of the 45 patients with refractory/relapsed AML was (36.25±8.40) months and the median follow up was (9±2.58) months. The one-year and two-years overall survival (OS) rate was (40.6±7.5) % and (23.7±7.0) %, respectively. Univariate analysis results demonstrated that age (p<0.05) and undergoing hematopoietic stem cell transplantation (HSCT) after relapse (p<0.01) were significantly related to OS in these patients. Conclusion: Age and whether to undergo HSCT after relapse are the key factors for the survival of patients with refractory/relapsed AML in our center. HSCT is still an effective salvage therapy for patients with refractory/relapsed AML. Our findings highlight the divergent outcomes of these patients and provide evidence to support the importance of timely HSCT after relapse, which is beneficial for clinicians to make clinical decisions in the future.

scholarly journals Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

2020 ◽  
Author(s):  
Linus Angenendt ◽  
Isabel Hilgefort ◽  
Jan-Henrik Mikesch ◽  
Bernhard Schlüter ◽  
Wolfgang E. Berdel ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myeloid Leukemia ◽  
Epstein Barr Virus Infection ◽  
Hematopoietic Stem ◽  
Acute Myeloid

AbstractLow intake of magnesium has been associated with the occurrence of lymphomas and decreased magnesium levels suppress the cytotoxic function of T cells and natural killer cells in patients with “X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia” (XMEN) syndrome. These cell types are also important mediators of immune-mediated effects after allogeneic hematopoietic stem cell transplantation. Here, we show that high posttransplant magnesium levels independently associate with a lower incidence of relapse, a higher risk of acute graft-versus-host disease, and a higher non-relapse mortality in 368 patients with acute myeloid leukemia from our center. Magnesium serum levels might impact on donor-cell-mediated immune responses in acute myeloid leukemia.

Sign in / Sign up

Export Citation Format

Share Document